Bausch + Lomb (BLCO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Bausch + Lomb reported $1.28 billion in revenue for Q3 2025, a 7.1% year-over-year increase, with an EPS of $0.18 compared to $0.17 a year ago [1] - The revenue was slightly below the Zacks Consensus Estimate by -0.04%, while the EPS exceeded the consensus estimate by +12.5% [1] Revenue Breakdown - Vision Care revenues were $736 million, slightly below the average estimate of $743.74 million, reflecting a year-over-year increase of +7.6% [4] - Surgical revenues reached $215 million, in line with the average estimate of $214 million, marking a +4.4% change year-over-year [4] - Pharmaceuticals revenues totaled $330 million, surpassing the average estimate of $327.18 million, with a year-over-year increase of +7.8% [4] - Other revenues were reported at $4 million, below the two-analyst average estimate of $5 million, showing no change year-over-year [4] Stock Performance - Bausch + Lomb shares returned +0.9% over the past month, underperforming compared to the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]